← FDA DRUG APPROVALS

FDA NDA · NDA019625

ELOCON

Sponsor: ORGANON

APPLICATION
NDA019625
TYPE
NDA
ORIGINAL APPROVAL
1987-05-06
LATEST ACTION
2026-07-06
ROUTE
TOPICAL
DOSAGE FORM
CREAM
MARKETING STATUS
Discontinued

Products

ELOCON · ReferenceDiscontinued
MOMETASONE FUROATE 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CREAM · TOPICAL
ELOCONDiscontinued
MOMETASONE FUROATE 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CREAM · TOPICAL

Approval history

2026-07-06Labeling · Supplement 27 · standard — Letter ↗AP
2018-05-21Labeling · Supplement 26 · standard — Label ↗AP
2013-04-19Efficacy · Supplement 24 · standard — Letter ↗AP
2002-07-17Efficacy · Supplement 13 · standard — Label ↗AP
2002-07-17Labeling · Supplement 12 · standard — Letter ↗AP
2000-04-13Manufacturing (CMC) · Supplement 11 · standardAP
1998-12-28Manufacturing (CMC) · Supplement 9 · standardAP
1998-11-10Manufacturing (CMC) · Supplement 10 · standardAP
1998-06-05Manufacturing (CMC) · Supplement 8 · standardAP
1998-05-21Manufacturing (CMC) · Supplement 7 · standardAP
1997-03-07Manufacturing (CMC) · Supplement 6 · standardAP
1996-04-16Manufacturing (CMC) · Supplement 5 · standardAP
1995-10-03Efficacy · Supplement 3AP
1991-09-25Manufacturing (CMC) · Supplement 4 · standardAP
1987-10-29Manufacturing (CMC) · Supplement 1 · standardAP
1987-05-06Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →